SCHEMBL1210126

SCHEMBL1210126

C/C(=N\[S@@+]([O-])C(C)(C)C)c1ccc2[nH]ncc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 4/20 0.43
WNT3A P56704 4/20 0.43
CYP2D6 P10635 3/20 0.42
SLC6A2 P23975 3/20 0.42
SLC6A4 P31645 3/20 0.42
SLC6A3 Q01959 3/20 0.42
ROCK1 Q13464 3/20 0.41
ROCK2 O75116 2/20 0.41
CHEK1 O14757 1/20 0.40
AURKA O14965 1/20 0.40
DAPK3 O43293 1/20 0.40
JAK2 O60674 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
PAK4 O96013 1/20 0.40
NTRK1 P04629 1/20 0.40
FYN P06241 1/20 0.40
CSF1R P07333 1/20 0.40
RET P07949 1/20 0.40
MET P08581 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1210124 1.00 CTNNB1 (0.43) CTNNB1WNT3ACYP2D6SLC6A2SLC6A4
SCHEMBL29915578 1.00 CTNNB1 (0.43) CTNNB1WNT3ACYP2D6SLC6A2SLC6A4
SCHEMBL1210136 1.00 CTNNB1 (0.43) CTNNB1WNT3ACYP2D6SLC6A2SLC6A4
SCHEMBL1210130 1.00 CTNNB1 (0.43) CTNNB1WNT3ACYP2D6SLC6A2SLC6A4
SCHEMBL1210133 1.00 CTNNB1 (0.43) CTNNB1WNT3ACYP2D6SLC6A2SLC6A4
SCHEMBL264383 0.77 RAB9A (0.57) CTNNB1WNT3AROCK1ROCK2JAK2
SCHEMBL264384 0.77 RAB9A (0.57) CTNNB1WNT3AROCK1ROCK2JAK2
SCHEMBL16617733 0.73 CTNNB1 (0.56) CTNNB1WNT3AROCK1ROCK2JAK2
SCHEMBL15447204 0.73 AKT1 (0.32) MAPTCSNK2A1KDM4EALDH1A1
SCHEMBL19088309 0.73 AKT1 (0.32) MAPTCSNK2A1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020114949-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-06-11 WO disclosed
EP-2240467-B1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME EVOTEC AG (DE) 2013-03-20 EP disclosed
US-20130045973-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME EVOTEC AG 2013-02-21 US disclosed
US-8163901-B2 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same EVOTEC AG (DE) 2012-04-24 US disclosed
US-20110028465-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME EVOTEC AG (DE) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130045973-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 CTNNB1 3770/4885WNT3A 2895/4885CYP2D6 3016/4885
US-20110028465-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 CTNNB1 3770/4885WNT3A 2895/4885CYP2D6 3016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.